Zydus, MSN Launch First Generic Adempas® in the U.S. Kumar Jeetendra | October 17, 2026 Zydus Lifesciences Limited (Zydus), in partnership with MSN Laboratories Private Limited (MSN), today announced the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first companies to launch a generic version of Adempas® (riociguat) in the U.S. market. The product …
Mankind Pharma Enters CAR-T Therapy with Armed Cell Acquisition Kumar Jeetendra | October 17, 2026 As a part of its long term strategy to build a global innovation-led pharmaceutical business, Mankind Pharma (BSE: 543904 | NSE: MANKIND) through its subsidiary Mankind Pharma (Netherlands) B.V., has entered into a definitive agreement under which Mankind Pharma will acquire a majority stake in Armed Cell Therapeutics B.V., a Belgium-incorporated biotechnology company developing next-generation …
Zydus Launches Season 3 of ‘Easiest Exam’ Breast Cancer Campaign Kumar Jeetendra | October 17, 2026 Marking Breast Cancer Awareness Month, Zydus has launched Season 3 of its nationwide ‘Easiest Exam’ campaign, encouraging women to spend just three minutes every month checking their breasts for unusual changes. Breast cancer continues to be a growing health concern in India. A recent study found that the country’s breast cancer incidence rate increased from …
Cipla Partners with Qilu Pharma for Keytruda® Biosimilar in the US Kumar Jeetendra | October 12, 2026 Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA) today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States. As part of the agreement, Qilu …
Cipla USA Launches Pomalidomide Capsules Kumar Jeetendra | October 12, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as “Cipla”), today announced the launch of Pomalidomide Capsules, a generic equivalent of Pomalyst® by Celgene Corporation, a Bristol-Myers Squibb company. Cipla USA Launches Pomalidomide Capsules in All Strengths Pomalidomide capsules …
Acrotech Launches ADQUEY™ and Enters U.S. Dermatology Market Kumar Jeetendra | October 12, 2026 Acrotech Biopharma Inc., a biopharmaceutical company focused on developing and commercializing innovative proprietary medicines, today announced the U.S. launch of ADQUEY™ (difamilast 1%) ointment, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients 2 years of age and older. Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma …
Eppendorf launches new refrigerated Centrifuge 5811 R Kumar Jeetendra | September 14, 2026 Eppendorf is launching the new Centrifuge 5811 R,a refrigerated, multipurpose benchtop centrifuge designed to support a wide range of laboratory workflows. It builds on the proven performance and versatility of the Centrifuge 5810 R. Known and loved in laboratories around the world for many decades, the Centrifuge 5810 R has received an impactful update. The …
Cipla, SBP Group Sign Exclusive License for HER2 Bispecific ADC Kumar Jeetendra | September 7, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA) (“Cipla”) and Sino Biopharmaceutical Limited (HKEX: 1177) (“SBP Group”) today announced that SBP Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (“ADC”). …
Cipla Receives U.S. FDA Approval for Generic Advair Diskus® Kumar Jeetendra | July 28, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as “Cipla”), today announced that Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol …
Alembic Pharma Receives USFDA Approval for Dapsone Gel 5% Kumar Jeetendra | June 29, 2026 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC. Dapsone Gel is indicated for the …
2026 Watchlist: Top 10 CROs Driving Innovation in Drug Development Kumar Jeetendra | June 24, 2026 The role of AI in research promises to bring new drugs to market faster than ever before. Drug development is complex. As a result, many of the best contract research organizations (CROs) have stopped being simple vendors or service delivery partners. They have become partners in strategic innovation. The CRO Leaders to Watch in 2026: …
Aurobindo Pharma USA Secures FTC Approval for Lannett Deal Kumar Jeetendra | June 22, 2026 Aurobindo Pharma USA, Inc. a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (“Lannett”). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to …
